Gilead Sciences Inc (GILD)

GILD (NASDAQ:Drugs) EQUITY
$79.25
neg -1.37
-1.70%
Today's Range: 78.64 - 79.90 | GILD Avg Daily Volume: 10,654,800
Last Update: 09/27/16 - 4:00 PM EDT
Volume: 13,199,386
YTD Performance: -20.33%
Open: $79.32
Previous Close: $80.62
52 Week Range: $77.92 - $120.37
Oustanding Shares: 1,319,658,489
Market Cap: 107,380,611,250
6-Month Chart
TheStreet Ratings Grade for GILD
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 10 8 8 8
Moderate Buy 1 1 2 2
Hold 8 9 7 7
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.89 2.06 1.94 1.94
Latest Dividend: 0.47
Latest Dividend Yield: 2.31%
Dividend Ex-Date: 09/14/16
Price Earnings Ratio: 7.18
Price Earnings Comparisons:
GILD Sector Avg. S&P 500
7.18 6.80 12.90
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
0.19% -19.49% 28.38%
GROWTH 12 Mo 3 Yr CAGR
Revenue 31.10 2.40 0.49
Net Income 50.10 6.00 0.90
EPS 62.00 6.20 0.92
Earnings for GILD:
EBITDA 23.29B
Revenue 32.64B
Average Earnings Estimates
Qtr (09/16) Qtr (12/16) FY (12/16) FY (12/17)
Average Estimate $2.77 $2.72 $11.47 $11.52
Number of Analysts 8 6 10 6
High Estimate $2.95 $2.92 $12.01 $13.03
Low Estimate $2.57 $2.49 $10.92 $10.57
Prior Year $3.19 $3.27 $12.45 $11.47
Growth Rate (Year over Year) -13.21% -16.82% -7.87% 0.45%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
RMPIA

bearishGilead downgraded at Leerink

Sep 27, 2016 | 7:18 AM EDT
GILD was downgraded to Market Perform, Leerink Partners said. $94 price target. Hepatitis C market is eroding faster than expected.
RMPIA
By

Jim Cramer

 | Sep 23, 2016 | 6:44 AM EDT
Apart from the Fed, there are other factors that make investors nervous.
RMPIA
By

John Reese

 | Sep 16, 2016 | 3:00 PM EDT
Emulate Graham and Buffett with Greenblatt’s 'Magic Formula' screen.
RMPIA
By

Timothy Collins

 | Sep 16, 2016 | 1:30 PM EDT
The once-mighty biotech has fallen, but entry opportunities will surface.
RMPIA
By

Carolyn Boroden

 | Sep 12, 2016 | 9:00 AM EDT
It's been a nasty decline, but if we rally, these three have best charts.
RMPIA
By

David Katz

 | Sep 9, 2016 | 7:00 AM EDT
If and when interest rates go up, this basket of stocks should continue to do well.
RMPIA

updateCiti Biotech Conf.

Sep 7, 2016 | 7:16 AM EDT
Thomson ONE
Citi Biotech Conference (Day 1 of 2) - 09/07/16 - 09/08/16 Boston, MA
RMPIA

bullishGilead upgraded at Jefferies

Sep 6, 2016 | 7:01 AM EDT
GILD was upgraded to Buy, Jefferies said. $91 price target. Valuation call, as the stock is trading at less than 7x earnings.
RMPIA

bearishGilead estimates, target cut at Jefferies

Aug 31, 2016 | 6:59 AM EDT
Shares of GILD now seen reaching $91, according to Jefferies. Estimates also reduced, given lower expected Harvoni sales. Hold rating.
RMPIA
By

Bret Jensen

 | Aug 22, 2016 | 11:48 AM EDT
Stocks are back to flat to slightly lower overall, but biotechs are up some 1.5% following the announcement from Pfizer (PFE) of plans to buy Medivation (MDVN) for $14 billion.
There has been a consistent pattern from the oil markets in the past year. OPEC makes nois...
yesterday we rolled up a prior play and added an at the money on this momentum name. BO...
yesterday we added some WDC calls (sorry it's late, i'm still in Chicago and had some inte...
Markets having a nice day as evidently investors believe Hillary Clinton held her own in t...

REAL MONEY PRO'S BEST IDEAS

News Breaks

Powered by
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.